129560-99-2

Usage

Uses

Used in Pharmaceutical Industry:
4-(2,2,2-TRIFLUOROETHOXY)PHENOL is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with enhanced properties. Its stability and reactivity make it a suitable candidate for creating complex molecular structures.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(2,2,2-TRIFLUOROETHOXY)PHENOL is utilized as an intermediate in the production of agrochemicals, helping to formulate more effective and stable pesticides and other agricultural chemicals that can withstand environmental conditions.
Used in Polymer and Material Science:
4-(2,2,2-TRIFLUOROETHOXY)PHENOL is used as a building block in the production of polymers and materials, where its stability and chemical properties are leveraged to create materials with specific characteristics for various applications.

Upstream product

• 75-89-8 2,2,2-trifluoroethanol 
• 65109-75-3 N-(phenoxy)-4-methylbenzenesulfonamide 
• 1004322-73-9 4-chloro-3-trimethylsilanylphenol 
• 540-38-5 p-Iodophenol 
• 103-16-2 4-Benzyloxyphenol 
• 200956-20-3 1-(benzyloxy)-4-(2,2,2-trifluoroethoxy)benzene 
• 76579-44-7 1-(4-(2,2,2-trifluoroethoxy)phenyl)ethan-1-one 

Downstream Products

• 128140-39-6 4'-Pentyl-bicyclohexyl-4-carboxylic acid 4-(2,2,2-trifluoro-ethoxy)-phenyl ester 
• 444341-80-4 2-chloro-4-(2,2,2-trifluoroethoxy)phenol 
• 104-94-9 4-methoxy-aniline 
• 1138244-64-0 ethyl 4-(2,2,2-trifluoroethoxy)-1-hydroxycyclohexanecarboxylate 
• 1138244-63-9 1-hydroxy-4-(2,2,2-trifluoroethoxy)cyclohexanecarbonitrile 
• 1138244-29-7 4-(2,2,2-trifluoroethoxy)cyclohexanone 
• 1138244-30-0 4-(2,2,2-trifluoroethoxy)cyclohexanol 
• 444341-81-5 3-bromopropyl 2-chloro-4-(2,2,2-trifluoroethoxy)phenyl ether 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: -CH2-, - CH2-CH2-, -CH2-CH2-CH2-, or -CH2-O-CH2-; and Z represents a hydrogen atom or a hydroxyl group.]

NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

A compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof: [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—; and Z represents a hydrogen atom or a hydroxyl group.]

Direct synthesis of anilines and nitrosobenzenes from phenols

A one-pot synthesis of anilines and nitrosobenzenes from phenols has been developed using an ipso-oxidative aromatic substitution (iSOAr) process. The products are obtained in good yields under mild and metal-free conditions. The leaving group effect on reactions that proceed through mixed quionone monoketals has also been investigated and a predictive model has been established.

The β effect of silicon in phenyl cations

Irradiation of chloroanisoles, phenols, and N,N-dimethylanilines bearing a trimethylsilyl (TMS) group in the ortho position with respect to the chlorine atom caused photoheterolysis of the Ar-Cl bond and formation of the corresponding ortho-trimethylsilylphenyl cations in the triplet state. The β effect of silicon on these intermediates has been studied by comparing the resulting chemistry in alcoholic solvents with that of the silicon-free analogues and by computational analysis (at the UB3LYP/6-311+G(2d,p) level in MeOH). TMS groups little affect the photophysics and the photocleavage of the starting phenyl chlorides, while stabilizing the phenyl cations, both in the triplet (ca. 4 kcal/mol per group) and, dramatically, in the singlet state (9 kcal/mol). As a result, although triplet phenyl cations are the first formed species, intersystem crossing to the more stable singlets is favored with chloroanisoles and phenols. Indeed, with these compounds, solvent addition to give aryl ethers (from the singlet) competed efficiently with reduction or arylation (from the triplet). In the case of the silylated 4-chloro-N,N- dimethylaniline, the triplet cation remained in the ground state and trapping by π nucleophiles remained efficient, though slowed by the steric bulk of the TMS group. In alcohols, the silyl group was eliminated via a photoinduced protiodesilylation during the irradiation. Thus, the silyl group could be considered as a directing, photoremovable group that allowed shifting to the singlet phenyl cation chemistry and was smoothly eliminated in the same one-pot procedure.

(2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents

A SAR study was conducted on chromane-2-carboxylic acid toward selective PPARα agonisim. As a result, highly potent, and selective PPARα agonists were discovered. The optimized compound 43 exhibited robust lowering of total cholesterol levels in hamster and dog animal models.

Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders

A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, d

Liquid Crystals with Polar Substituents Containing Fluorine: Synthesis and Physical Properties

Liquid crystalline compounds with various polar terminal groups containing fluorine have been prepared (see below formula 1 with Z = S-CHF2, S-CF3, SO-CHF2, SO-CF3, SO2-CHF2, SO2-CF3, SO2F, OCH2CF3, CO-OCH2CF3, CO-CF3, CO-CF2Cl, CO-CF2H, CO-CF2-CH3, CO-CF2-C3H7).The synthesis of these compounds is outlined here and their physical properties (phase transitions, dielectric anisotropy, birefringence, viscosity) are discussed.

Novel substituted aromatic compounds

Substituted phenoxy, phenylthio and anilino compounds, intermediates therefor, synthesis thereof, and their use for the control of pests.

Acid-Catalyzed Solvolysis of N-Sulfonyl- and N-Acyl-O-arylhydroxylamines. Phenoxenium Ions

The acid-catalyzed reaction of N-acyl- and N-sulfonyl-O-arylhydroxylamines with benzene proceeded quite smoothly to give 2- and 4-hydroxybiphenyls.The results of product analysis, the orientation of the reaction, and the effects of substituents on the nitrogen atom and on the phenyl ring suggested a mechanism that involves a phenoxenium ion.The phenoxenium ion was trapped by benzene and other various nucleophiles.